FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response
December 22, 2017 -- The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotinib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 22, 2017 Category: Drugs & Pharmacology Source Type: news
Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Treatment-Free Remission in CML Sustainable After Nilotinib
Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks. (Source: CancerNetwork)
Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia & Lymphoma News Source Type: news
TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Cancer Drug That Might Slow Parkinson's, Alzheimer's Headed For Bigger Tests
In a preliminary study, the cancer drug nilotinib seemed to help patients with Parkinson's and dementia. Now two larger and more rigorous studies of the drug are under way.(Image credit: Zephyr/Science Source) (Source: NPR Health and Science)
Source: NPR Health and Science - March 15, 2017 Category: Consumer Health News Authors: Jon Hamilton Source Type: news
Tasigna Capsules (Nilotinib Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 6, 2017 Category: Drugs & Pharmacology Source Type: news
The Mast Cell: New Target in SpA? (CME/CE)
(MedPage Today) -- Nilotinib shows biomarker, clinical benefits in peripheral spondyloarthritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 12, 2016 Category: Primary Care Source Type: news
Nilotinib Shows Early Safety in Parkinson' Dementia Nilotinib Shows Early Safety in Parkinson' Dementia
Dr Alan Jacobs details a small proof-of-concept study, the first to treat persons with advanced Parkinson ' s with a tyrosine kinase inhibitor.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 25, 2016 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients
A propensity score –matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Leukemia drug shows early promise for treating Parkinson's disease and dementia
(IOS Press) Parkinson's disease is the second most common neurodegenerative disorder that causes a range of motor and non-motor symptoms. During the course of the disease, dopamine-producing neurons are lost and bundles of proteins known as Lewy bodies form in the brain. A study reported in the Journal of Parkinson's Disease provided molecular evidence that the FDA-approved leukemia drug nilotinib may restore brain dopamine and reduce toxic proteins associated with LB formation in PD and dementia patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2016 Category: Global & Universal Source Type: news
Frontline nilotinib supported for newly diagnosed CP–CML
Long-term results from the ENESTnd trial indicate a favourable risk–benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase–chronic myeloid leukaemia diagnosis. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Cancer Drug Shows Promise in Parkinson's Dementia Cancer Drug Shows Promise in Parkinson's Dementia
Low-dose nilotinib improved biomarkers, cognition, and motor skills in a small phase 1 study of patients with Parkinson's dementia and Lewy body dementia. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 21, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Parkinson's victims 'brought back to life' by cancer drug nilotinib
Researchers in Washington now hope the 'life-changing' drug - a leukaemia treatment called nilotinib - will also work for those with brain conditions such as Alzheimer's. (Source: the Mail online | Health)
Source: the Mail online | Health - October 19, 2015 Category: Consumer Health News Source Type: news
Medical News Today: Man walks again as cancer drug is trialled for Parkinson's
Nilotinib, a drug used to treat leukemia, has been trialled with success on a small group with Parkinson's and Lewy body dementia, improving cognitive ability and biomarkers (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 19, 2015 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news
Man walks again as cancer drug is trialled for Parkinson's
Nilotinib, a drug used to treat leukemia, has been trialled with success on a small group with Parkinson's and Lewy body dementia, improving cognitive ability and biomarkers (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - October 19, 2015 Category: Neurology Tags: Parkinson's Disease Source Type: news
